Skip to Content

Nyxoah SA Ordinary Shares NYXH

Morningstar Rating
€7.96 +0.18 (2.31%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NYXH is trading at a 682% premium.
Price
€7.75
Fair Value
€76.75
Uncertainty
Extreme
1-Star Price
€882.12
5-Star Price
€6.37
Economic Moat
Nql
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NYXH is a good fit for your portfolio.

Trading Information

Previous Close Price
€7.78
Day Range
€7.808.14
52-Week Range
€3.7917.60
Bid/Ask
€7.80 / €8.20
Market Cap
€273.51 Mil
Volume/Avg
32,811 / 39,593

Key Statistics

Price/Earnings (Normalized)
Price/Sales
43.49
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Small Growth
Total Number of Employees
147

Comparables

Valuation

Metric
NYXH
INVA
LUNG
Price/Earnings (Normalized)
9.96
Price/Book Value
2.831.442.07
Price/Sales
43.494.443.08
Price/Cash Flow
8.24
Price/Earnings
NYXH
INVA
LUNG

Financial Strength

Metric
NYXH
INVA
LUNG
Quick Ratio
3.608.515.98
Current Ratio
3.9410.426.95
Interest Coverage
−89.949.81−17.05
Quick Ratio
NYXH
INVA
LUNG

Profitability

Metric
NYXH
INVA
LUNG
Return on Assets (Normalized)
−30.65%15.69%−21.78%
Return on Equity (Normalized)
−41.00%29.88%−31.74%
Return on Invested Capital (Normalized)
−35.81%17.71%−24.90%
Return on Assets
NYXH
INVA
LUNG
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
PrhjlwngzyRmkbg$152.5 Bil
Becton Dickinson & Co
BDX
CslfwzbBkmyvyq$67.3 Bil
Alcon Inc
ALC
YvcswgsyWpgcbmr$43.5 Bil
ResMed Inc
RMD
HlrbggptGlcvgzf$30.9 Bil
Coloplast A/S ADR
CLPBY
JfwxqqgwqTmtj$27.5 Bil
West Pharmaceutical Services Inc
WST
BfgpxqydxFhdfk$24.6 Bil
The Cooper Companies Inc
COO
MwhbrlzhBkvkm$18.4 Bil
Baxter International Inc
BAX
GzvgfdtwcXwlpwz$17.3 Bil
Hologic Inc
HOLX
JhqqbsqQsyhld$16.7 Bil
AptarGroup Inc
ATR
QdmzfpbbTvmgd$9.7 Bil

Sponsor Center